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Background: Microalbuminuria is a marker of systemic endothelial dysfunction. We studied the relationship
between peritoneal protein loss in peritoneal dialysis (PD) patients, which is conceptually analogous to
microalbuminuria in non-uremic patients, and pre-existing vascular disease in new PD patients.
Methods: Peritoneal total protein and albumin loss were quantified within 2 months of initiation of dialysis in
44 consecutive new PD patients, together with a standard peritoneal equilibration test. The results were compared
according to the presence of cardiovascular disease (CVD) prior to initiation of dialysis, lean body mass, and
serum albumin and C-reactive protein (CRP) concentrations.
Results: The dialysate albumin concentration was closely correlated with the creatinine dialysate-to-plasma
ratio at 4 hours (r = 0.601, p < 0.001). It was higher in patients with pre-existing CVD than in those without,
when patients were analyzed according to diabetic status (one-way ANOVA, p = 0.004). In diabetic patients,
the dialysate albumin concentration was significantly higher in patients with pre-existing CVD than in those
without (0.754 ( 0.273 vs 1.088 ( 0.280 mg/+mol creatinine, p = 0.04). Multivariate analysis showed that only
diabetic status and dialysate albumin concentration, but not peritoneal transport status or serum CRP, were
independent predictors of pre-existing CVD. Although dialysate protein loss accounted for only 10.5 ( 4.4%
of total protein catabolism, the dialysate protein level was significantly correlated with serum albumin
concentration (r = –0.457, p = 0.002), percentage of lean body mass (r = –0.558, p < 0.001), and serum CRP
concentration (r = 0.434, p = 0.003).
Conclusions: Patients with CVD prior to initiation of dialysis have higher levels of dialysate albumin and total
protein excretion, indicating that dialysate protein loss is a marker of underlying CVD. Dialysate protein and
albumin excretion may provide a simple and convenient measure of vascular disease and endothelial dysfunction
in PD patients. [Hong Kong J Nephrol 2004;6(1):31–7]
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INTRODUCTION
Inflammation plays a pivotal role in the pathogenesis
of atherosclerotic disease and malnutrition [1,2].
Elevated plasma C-reactive protein (CRP) con-
centrations, induced by other pro-inflammatory cy-
tokines, are associated with the risk of myocardial
infarction [3] and mortality [4] in peritoneal dialysis
(PD) patients. On the other hand, pro-inflammatory
cytokines can cause protein catabolism and malnutrition
[5–7]. Several studies have found that inflammation
alone, or in combination with a low protein intake,
causes hypoalbuminemia in dialysis patients [8,9]. The
complicated interactions between malnutrition,
inflammation and atherosclerotic diseases are now
known as the MIA syndrome [10].
How does inflammation cause atherosclerosis? One
possibility is that inflammation induces endothelial
dysfunction which, at least in non-uremic patients, has
important roles in the pathogenesis of atherosclerosis
[11]. Endothelial dysfunction can be measured using a
panel of serum markers (e.g. soluble intercellular adhe-
sion molecule 1, sICAM-1, and vascular cell adhesion
molecule 1, VCAM-1) [12–14], but all are expensive
and none is applicable for routine clinical use. Inte-
restingly, microalbuminuria potentially represents
a simple and inexpensive marker of endothelial
dysfunction [15]. The relationship between microalbu-
minuria and cardiovascular disease (CVD) was first
noted in diabetic patients [16], but it has since been
documented in non-diabetic populations [17,18]. Al-
though the exact nature of this association is not fully
understood, it has been proposed that microalbumin-
uria represents a systemic endothelial abnormality
[15], affecting not only glomerular capillaries, but also
arterial and arteriolar intimal function, thereby promot-
ing transvascular escape of atherogenic molecules [19].
If microalbuminuria is a result of systemic endo-
thelial dysfunction, we predict that peritoneal albumin
loss in PD patients, which is conceptually analogous
to microalbuminuria in non-uremic patients, would be
a surrogate marker of endothelial dysfunction and a
predictor of CVD in PD patients. This pilot study
examined the relationship between peritoneal protein
loss, pre-existing vascular disease and markers of sys-
temic inflammation in new PD patients.
PATIENTS AND METHODS
Patient selection
We studied consecutive new PD patients. Patients un-
derwent a standard peritoneal equilibration test (PET)
[20] within 2 months of the commencement of PD,
when they were in a euvolemic state. On the day prior
to PET, 24-hour urine and dialysate collection was
performed to assess nutritional status. The presence of
diabetes and a history of CVD at initiation of dialysis
were recorded. CVD was defined as angina, class III–
IV congestive heart failure, or a history of previous
myocardial infarction, cerebrovascular accident or
amputation for vascular disease.
Study of peritoneal transport
PET was performed using the method of Twardowski
et al [20]. Briefly, a 4-hour dwell study was carried out
with 2 L of dextrose 2.5% dialysis fluid (Dianeal,
Baxter-Travenol, Deerfield, IL, USA). Dialysate
creatinine and glucose concentrations were measured
at 0, 2 and 4 hours, and plasma creatinine and glucose
concentrations at 2 hours. Drainage and ultrafiltration
volumes at 4 hours were documented. Creatinine
dialysate-to-plasma ratios (D/P) at 0, 2, and 4 hours
were calculated after correction for glucose inter-
ference. The results were plotted on a PET graph.
Patients were classified into high, high-average, low-
average, and low transporters, as described previously
[20]. Mass transfer area coefficients (MTAC) of
creatinine normalized for body surface area (BSA) were
calculated using the formula described by Krediet et al
[21]. BSA was determined by nomogram from body
weight and height [22].
Peritoneal protein and albumin excretion rate
During PET, dialysate albumin and total protein
concentrations at 4 hours were determined using a
fully automated analyzer (Konelab 60, Thermo
Clinical Labsystems, Thermo Electron Corporation,
Waltham, MA, USA), and the concentrations were
adjusted for dialysate creatinine concentration. In all
measurements, creatinine concentration in the
dialysate was corrected for glucose interference
according to a formula provided by our laboratory
[23].
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Peritoneal protein loss, nutrition and inflamma-
tion markers
On the day prior to PET, 24-hour urine and dialysate
collection was performed. Lean body mass was calculat-
ed according to the formula described by Forbes and
Brunining [24], and normalized to percentage using the
ideal body weight, determined from height and sex
according to a standard formula validated in southern
Chinese [25]. The protein catabolic rate was calculated
using the modified Bergstrom’s formula [26]. Daily pro-
tein loss in the dialysate was measured using a standard
biochemical method. Serum albumin was measured us-
ing the bromcresol purple method. Serum CRP was mea-
sured with the Tina-quant CRP (Latex) ultra-sensitive
assay (Roche Diagnostics GmbH, Mannheim, Germany).
Statistical analysis
Statistical analysis was performed using SPSS version
11.0 (SPSS Inc, Chicago, IL, USA) for Windows.
Results are expressed as mean ( standard deviation
unless otherwise specified. Comparisons between
groups were performed using the Chi-squared test,
Student’s t test or Kruskal-Wallis test as appropriate.
Correlations between continuous variables were
examined using Pearson’s correlation coefficient or
Spearman’s rank correlation coefficient, as appropriate.
In order to explore the independent role of dialysate
albumin concentration as a marker of inflammation and
CVD, a backward stepwise logistic regression model
was constructed with CVD as the dependent variable,
and diabetes, creatinine D/P at 4 hours, serum CRP
concentration and dialysate albumin concentration
adjusted for creatinine as independent variables. A p
value of less than 0.05 was considered significant. All
probabilities were two-tailed.
RESULTS
We studied 44 patients in total. Demographic and
baseline clinical information are summarized in the
Table. The average creatinine D/P at 4 hours was 0.628 (
0.145, and the average MTAC of creatinine was 9.63 (
6.10 mL/min. There were 11 (25.0%) low transporters,
16 (36.4%) low-average transporters, 11 (25.0%) high-
average transporters, and six (13.6%) high transporters.
The mean unadjusted dialysate albumin concentra-
tion was 311.0 ( 125.1 mg/L, and the dialysate total
protein concentration was 502.0 ( 201.0 mg/L. The
average total nucleated cell count in the dialysis effluent
was 4.0 ( 0.7/mL.
Relationship between dialysate albumin concen-
tration and peritoneal transport
After adjustment for dialysate creatinine concentration,
the dialysate albumin concentration was closely cor-
related with creatinine D/P at 4 hours (Pearson’s r =
0.601, p < 0.001) (Figure 1) and MTAC of creatinine
(r = 0.610, p < 0.001), but not with the net ultrafiltra-
tion volume as determined by standard PET (r = –0.08,
p = 0.6). Similarly, the dialysate total protein concentra-
tion was correlated with creatinine D/P at 4 hours
(r = 0.577, p < 0.001) and MTAC of creatinine (r = 0.563,
p < 0.001), but not with net ultrafiltration volume (r =
–0.13, p = 0.4).
Relationship between dialysate albumin concen-
tration and CVD
Dialysate albumin concentration was marginally higher
in new PD patients with pre-existing CVD than in those
without (0.680 ( 0.253 vs 0.717 ( 0.265 mg/+mol
creatinine), but the difference was not statistically
significant. The difference became much more obvious
when patients were analyzed according to their diabetic
status (Kruskal-Wallis test, p = 0.018) (Figure 2A). In
diabetic patients, the dialysate albumin concentration
was significantly higher in patients with pre-existing
CVD than in those without (0.754 ( 0.273 vs 1.088 (
0.280 mg/+mol creatinine, p = 0.04). The dialysate total
protein concentration was also greater in patients with
pre-existing CVD than in those without (Kruskal-Wallis
test, p = 0.023), although the magnitude of the differ-
ence was less remarkable.
Creatinine D/P at 4 hours was higher in new PD
patients with pre-existing CVD than in those without
(0.619 ( 0.144 vs 0.643 ( 0.149, p = 0.6). The difference
remained statistically significant but clinically margin-
al when patients were analyzed according to diabetic
Table. Demographic and clinical data.
Number of patients 44
Gender (M/F) 18/26
Mean age ( SD (yr) 51.6 ( 14.7
Mean height ( SD (m) 1.63 ( 0.09
Mean weight ( SD (kg) 61.2 ( 13.7
Renal diagnosis, n (%)
   Glomerulonephritis 23 (52.3)
   Diabetic nephropathy 12 (27.3)
   Polycystic kidney 2 (4.5)
   Obstructive uropathy 2 (4.5)
   Others/unknown 5 (11.4)
Major comorbidity, n (%)
   Diabetes 14 (31.8)
   Cardiovascular disease 16 (36.4)
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status (Kruskal-Wallis test, p = 0.012) (Figure 2B).
Multivariate logistic regression analysis showed that
only diabetic status (adjusted odds ratio, OR, 40.7; 95%
confidence interval, CI, 4.2–396.4; p < 0.001) and
dialysate albumin concentration (adjusted OR, 1.01;
95% CI, 1.00–1.02; p = 0.033), but not creatinine D/P
at 4 hours and serum CRP, were independent predictors
of pre-existing CVD.
Relationship between dialysate albumin concen-
tration and malnutrition
In our patients, the total daily protein loss in dialysate
was 6.9 ( 3.0 g/day. In comparison, the total protein
catabolic rate was 69.0 ( 28.0 g/day. Dialysate protein
loss accounted for only 10.5 ( 4.4% of total protein
catabolism. However, there were significant inverse
correlations between dialysate protein loss and serum
albumin concentration (r = –0.457, p = 0.002) (Figure
3A), and percentage lean body mass (r = –0.558, p <
0.001) (Figure 3B). Furthermore, dialysate protein loss
had a significant correlation with serum CRP concen-
tration (Spearman’s r = 0.334, p = 0.027) (Figure 3C).
DISCUSSION
In the present study, patients with CVD prior to initia-
tion of dialysis had higher levels of dialysate albu-
min and total protein excretion, indicating that dialysate
protein loss is a marker of underlying vascular disease
and, as a consequence, of CVD, rather than the cause
of chronic fluid overload. Furthermore, although dialy-
sate protein loss makes only a small contribution to
whole body protein catabolism, it is strongly corre-
lated with nutritional indices and, more remarkably, is
a marker of systemic inflammation.
Our finding provides an alternative explanation for
the association between peritoneal transport status and
morbidity in PD patients [27,28] (Figure 4). Tradi-
tionally, a high peritoneal transporter is believed to be
Figure 1. Correlation between creatinine dialysate-to-plasma ratio
(D/P) at 4 hours of standard peritoneal equilibration test and
dialysate albumin excretion.
Figure 2. Stepwise increase in (A) dialysate albumin excretion and (B) creatinine dialysate-to-plasma ratio (D/P) at 4 hours of standard
peritoneal equilibration test in patients with cardiovascular disease (CVD), diabetes mellitus (DM) and both conditions prior to initiation
of dialysis.
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prone to fluid retention and peritoneal protein loss,
which result in malnutrition and patient morbidity [27].
However, recent studies have shown that the association
between peritoneal transport status and malnutrition
exists before patients begin PD [28,29]. Our findings
would certainly explain this intriguing observation.
Endothelial dysfunction in PD patients has become
a hot topic in recent years. CVD and malnutrition are
major causes of mortality and morbidity in PD patients
[30,31]. In addition to the classic risk factors of
atherosclerosis such as diabetes, hypertension and
hyperlipidemia, uremia and possibly the dialysis pro-
cedure per se play important roles in the pathogenesis
of accelerated atherosclerosis in renal failure patients
[32]. However, the exact mechanisms by which uremia
and dialysis cause CVD remain unclear. Recent studies
have shown that endothelial dysfunction is an important
marker of systemic vascular disease. In fact, the
endothelium participates in a number of important
homeostatic and cellular functions that are essential
in preserving vascular functional integrity [33].
Endothelial dysfunction is responsible for inflam-
matory cell adhesion [34,35], an initial step in the
atherosclerotic process, as well as the triggering of acute
cardiovascular events [34,36]. In diabetic patients,
plasma VCAM-1 levels correlate with the thickness of
Figure 4. (A) Traditional view of MIA syndrome: malnutrition,
inflammation and atherosclerosis have complicated interactions;
peritoneal hyper-permeability is an independent event causing
excessive protein loss in dialysis effluent, which results in mal-
nutrition. (B) Our alternative explanation: inflammation induces
endothelial dysfunction, which is closely linked to atherosclerosis.
Endothelial dysfunction directly causes peritoneal hyper-
permeability to macromolecules (broad arrow), which manifests
as increased peritoneal protein loss. According to this model,
peritoneal transport status to small molecules is a surrogate marker
of peritoneal hyper-permeability to protein, accounting for the
association between peritoneal transport and cardiovascular
disease.
Figure 3. Relationship between dialysate total protein excretion
and (A) serum albumin concentration, (B) percentage of lean body
mass, and (C) serum C-reactive protein concentration.
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the intimal plus medial layers of the carotid arteries
[12], suggesting that the level of circulating VCAM-1
is a marker of atherosclerotic lesions [13,14].
Biochemical markers of endothelial dysfunction
have been unsatisfactory. In response to pro-inflam-
matory cytokines, endothelial cells express sICAM-1
and VCAM-1 [37,38]. Increased levels of circulating
adhesion molecules have been shown in patients
suffering from inflammatory diseases and sepsis [39,
40]. In in vivo models, pro-inflammatory cytokines
inhibit the formation of endothelium-dependent
hyperpolarizing factor that may contribute to endo-
thelial dysfunction [41]. In diabetic patients, an in-
creased serum CRP concentration is associated with
endothelial dysfunction [42]. Previous studies have
shown that PD patients have impaired endothelium-
dependent vasodilatation [43], but its relationship with
inflammation in PD patients has not been studied in
detail.
Our findings may provide new insight in the search
for biochemical markers of endothelial dysfunction.
Peritoneal albumin and protein excretion can be de-
termined using the same assay as that used to screen
for diabetic microalbuminuria, which is available in
most hospital laboratories. Dialysate albumin excretion
may provide a simple and convenient measure of
endothelial dysfunction in PD patients. Further large-
scale studies in this area are definitely needed.
ACKNOWLEDGMENT
This study was supported, in part, by The Chinese
University of Hong Kong research accounts 6900972
and 6900570.
REFERENCES
1. Maseri A. Inflammation, atherosclerosis, and ischemic events –
exploring the hidden side of the moon. N Engl J Med 1997;336:
1014–6.
2. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T,
Berglund L, et al. Strong association between malnutrition, in-
flammation, and atherosclerosis in chronic renal failure. Kidney
Int 1999;55:1899–911.
3. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM,
Campbell SB, et al. Is C-reactive protein a useful predictor of
outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001;
12:814–21.
4. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive
protein predicts all-cause and cardiovascular mortality in hemo-
dialysis patients. Am J Kidney Dis 2000;35:469–76.
5. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn
GL, Istfan NW. Infusion of tumor necrosis factor/cachectin pro-
motes muscle catabolism in the rat. A synergistic effect with inter-
leukin 1. J Clin Invest 1989;83:1614–22.
6. Bergstrom J, Wang T, Lindholm B. Factors contributing to
catabolism in end-stage renal disease patients. Miner Electrolyte
Metab 1998;24:92–101.
7. Barton BE. IL-6-like cytokines and cancer cachexia: consequences
of chronic inflammation. Immunol Res 2001;23:41–58.
8. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin
concentration in hemodialysis patients. Am J Kidney Dis 1997;
29:658–68.
9. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialy-
sate albumin loss are the main determinants of serum albumin in
peritoneal dialysis patients. Am J Kidney Dis 1997;30:923–7.
10. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom
J. Are there two types of malnutrition in chronic renal failure?
Evidence for relationships between malnutrition, inflammation
and atherosclerosis (MIA syndrome). Nephrol Dial Transplant
2000;15:953–60.
11. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F,
Delagrange D, Creager MA, et al. Systemic nature of endothelial
dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B–4B.
12. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama
S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in
atherosclerotic NIDDM patients. Diabetes 1997;46:2096–101.
13. Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular
cell adhesion molecule-1 (VCAM-1) as potential marker of
atherosclerosis. Thromb Haemost 1999;82(Suppl 1):38–43.
14. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A
major role for VCAM-1, but not ICAM-1, in early atherosclerosis.
J Clin Invest 2001;107:1255–62.
15. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction
and cardiovascular risk. Diabetes Metab 2000;26(Suppl 4):64–6.
16. Beilin J, Stanton KG, McCann VJ, Knuiman MW, Divitini ML.
Microalbuminuria in type 2 diabetes: an independent predictor of
cardiovascular mortality. Aust NZ J Med 1996;26:519–25.
17. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of
microalbuminuria in predicting cardiovascular mortality in treated
hypertensive men with and without diabetes mellitus. Risk Factor
Intervention Study Group. Am J Cardiol 1997;80:164–9.
18. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE,
Crijns HJ, et al. Microalbuminuria is common, also in a nondia-
betic, nonhypertensive population, and an independent indica-
tor of cardiovascular risk factors and cardiovascular morbidity.
J Intern Med 2001;249:519–26.
19. Adams MR, Kinlay S, Blake GJ, Orford JL, Ganz P, Selwyn AP.
Atherogenic lipids and endothelial dysfunction: mechanisms in the
genesis of ischemic syndromes. Annu Rev Med 2000;51:149–67.
20. Twardowski ZJ, Nolph KD, Prowant B, Ryan L, Moore H, Nielsen
MP. Peritoneal equilibration test. Perit Dial Bull 1987;7:138–47.
21. Krediet RT, Boeschoten EW, Zuyderhoudt FM, Strackee J, Arisz
L. Simple assessment of the efficacy of peritoneal transport in
continuous ambulatory peritoneal dialysis patients. Blood Purif
1986;4:194–203.
22. Noe DA. A body surface area nomogram based on the formula of
Gehan and George. J Pharm Sci 1991;80:501.
23. Mak TW, Cheung CK, Cheung CM, Leung CB, Lam CW, Lai
KN. Interference of creatinine measurement in CAPD fluid was
dependent on glucose and creatinine concentrations. Nephrol Dial
Transplant 1997;12:184–6.
24. Forbes GB, Brunining GJ. Urinary creatinine excretion and lean
body mass. Am J Clin Nutr 1976;29:1359–66.
25. The ROC’s Handbook of Diet, 2nd edition. Taipei: Department of
Health, Republic of China (Taiwan) 1994;20–1.
Hong Kong J Nephrol • April 2004 • Vol 6 • No 1 37
Peritoneal albumin excretion and endothelial dysfunction
26. Bergstrom J, Heimburger O, Lindholm B. Calculation of the
protein equivalent of total nitrogen appearance from urea ap-
pearance. Which formulas should be used? Perit Dial Int 1998;
18:467–73.
27. Wang T, Heimburger O, Waniewski J, Bergstrom J, Lindholm B.
Increased peritoneal permeability is associated with decreased
fluid and small-solute removal and higher mortality in CAPD
patients. Nephrol Dial Transplant 1998;13:1242–9.
28. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos
DG, Page D. Increased peritoneal transport is associated with de-
creased patient and technique survival for continuous ambulatory
peritoneal dialysis patients. J Am Soc Nephrol 1998;9:1285–92.
29. Szeto CC, Law MC, Wong TY, Leung CB, Li PK. Peritoneal
transport status correlates with morbidity but not longitudinal
change of nutritional status of continuous ambulatory peritoneal
dialysis patients – a two-year prospective study. Am J Kidney Dis
2001;37:329–36.
30. Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular
disease in peritoneal dialysis. Perit Dial Int 1996;16(Suppl 1):
S19–22.
31. Szeto CC, Wong TY, Leung CB, Wang AY, Law MC, Lui SF, et
al. Importance of dialysis adequacy in mortality and morbidity of
Chinese CAPD patients. Kidney Int 2000;58:400–7.
32. Prichard S. Major and minor risk factors for cardiovascular disease
in peritoneal dialysis. Perit Dial Int 2000;20(Suppl 2):S154–9.
33. Sato Y. Current understanding of the biology of vascular
endothelium. Cell Struct Funct 2001;26:9–10.
34. Poredos P. Endothelial dysfunction in the pathogenesis of
atherosclerosis. Clin Appl Thromb Hemost 2001;7:276–80.
35. Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman
SJ. Soluble forms of vascular adhesion molecules, E-selectin,
ICAM-1, and VCAM-1: pathological significance. Ann NY Acad
Sci 1992;667:324–31.
36. Kinlay S, Ganz P. Relation between endothelial dysfunction and
the acute coronary syndrome: implications for therapy. Am J
Cardiol 2000;86:10J–3J.
37. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, et
al. Inflammation, not hyperhomocysteinemia, is related to
oxidative stress and hemostatic and endothelial dysfunction in
uremia. Kidney Int 2001;60:1844–50.
38. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O.
Elevated serum levels of soluble adhesion molecules predict
death in pre-dialysis patients: association with malnutrition,
inflammation, and cardiovascular disease. Nephrol Dial Trans-
plant 2000;15:1624–30.
39. Tesar V, Masek Z, Rychlik I, Merta M, Bartunkova J, Stejskalova
A, et al. Cytokines and adhesion molecules in renal vasculitis and
lupus nephritis. Nephrol Dial Transplant 1998;13:1662–7.
40. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E,
Oberhollenzer F, et al. Chronic infections and the risk of carotid
atherosclerosis: prospective results from a large population study.
Circulation 2001;103:1064–70.
41. Kessler P, Popp R, Busse R, Schini-Kerth VB. Proinflamma-
tory mediators chronically downregulate the formation of the
endothelium-derived hyperpolarizing factor in arteries via a nitric
oxide/cyclic GMP-dependent mechanism. Circulation 1999;99:
1878–84.
42. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager
AM, et al. Plasma concentration of C-reactive protein is increased
in type I diabetic patients without clinical macroangiopathy and
correlates with markers of endothelial dysfunction: evidence for
chronic inflammation. Diabetologia 1999;42:351–7.
43. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ,
Stehouwer CD. Endothelium-dependent vasodilatation is impaired
in peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:
1782–6.
